Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.

More... (http://www.news-medical.net/news/20120319/Top-line-data-from-Provectus-PH-10-Phase-2-trial-on-plaque-psoriasis.aspx)